1-15 of 15
Cody J. Peer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

Sarah Jenkins, Wei Zhang, Seth M. Steinberg, Darryl Nousome, Nicole Houston, Xiaolin Wu, Terri S. Armstrong, Eric Burton, Dee Dee Smart, Ritu Shah, Cody J. Peer, Brett Mozarsky, Oluwatobi Arisa, William D. Figg, Tito R. Mendoza, Elizabeth Vera, Priscilla Brastianos, Scott Carter, Mark R. Gilbert, Carey K. Anders, Roisín M. Connolly, Carol Tweed, Karen L. Smith, Imran Khan, Stanley Lipkowitz, Patricia S. Steeg, Alexandra S. Zimmer
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1450–1459.
https://doi.org/10.1158/1078-0432.CCR-22-0855
Published: 14 April 2023
View article titled, Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
Open the PDF for Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

John A. Ligon, R. Taylor Sundby, Mary F. Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener, Ramaprasad Srinivasan, Melissa Spencer, Amanda Carbonell, Haiyan Lei, John Shern, Seth M. Steinberg, William D. Figg, Cody J. Peer, Sara Zimmerman, Josquin Moraly, Xia Xu, Stephen Fox, King Chan, Michael I. Barbato, Thorkell Andresson, Naomi Taylor, Karel Pacak, J. Keith Killian, Eva Dombi, W. Marston Linehan, Markku Miettinen, Richard Piekarz, Lee J. Helman, Paul Meltzer, Brigitte Widemann, John Glod
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 341–348.
https://doi.org/10.1158/1078-0432.CCR-22-2168
Published: 17 January 2023
View article titled, A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
Open the PDF for A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

Katie E. Hebron, Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, William J.E. Frye, Angela Kim, Stacey Stauffer, Olivia L. Perkins, Wenyue Sun, Kristine A. Isanogle, Christina M. Robinson, Amy James, Parirokh Awasthi, Priya Shankarappa, Xiaoling Luo, Haiyan Lei, Donna Butcher, Roberta Smith, Elijah F. Edmondson, Jin-Qiu Chen, Noemi Kedei, Cody J. Peer, Jack F. Shern, W. Douglas Figg, Lu Chen, Matthew D. Hall, Simone Difilippantonio, Frederic G. Barr, Robert L. Kortum, Robert W. Robey, Angelina V. Vaseva, Javed Khan, Marielle E. Yohe
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 472–487.
https://doi.org/10.1158/1078-0432.CCR-22-1646
Published: 17 January 2023
View article titled, The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Open the PDF for The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

Jing Wu, Ying Yuan, Debra A. Long Priel, Danielle Fink, Cody J. Peer, Tristan M. Sissung, Yu-Ting Su, Ying Pang, Guangyang Yu, Madison K. Butler, Tito R. Mendoza, Elizabeth Vera, Salman Ahmad, Christine Bryla, Matthew Lindsley, Ewa Grajkowska, Kelly Mentges, Lisa Boris, Ramya Antony, Nancy Garren, Christine Siegel, Nicole Lollo, Christine Cordova, Orwa Aboud, Brett J. Theeler, Eric M. Burton, Marta Penas-Prado, Heather Leeper, Javier Gonzales, Terri S. Armstrong, Katherine R. Calvo, William D. Figg, Douglas B. Kuhns, John I. Gallin, Mark R. Gilbert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (12): 3298–3306.
https://doi.org/10.1158/1078-0432.CCR-20-4730
Published: 15 June 2021
View article titled, Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Open the PDF for Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas in another window
Includes: Multimedia, Supplementary data
Journal Articles

Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma

Christine Alewine, Mehwish Ahmad, Cody J. Peer, Zishuo I. Hu, Min-Jung Lee, Akira Yuno, Jessica D. Kindrick, Anish Thomas, Seth M. Steinberg, Jane B. Trepel, William D. Figg, Raffit Hassan, Ira Pastan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 828–836.
https://doi.org/10.1158/1078-0432.CCR-19-2586
Published: 14 February 2020
View article titled, Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
Open the PDF for Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Kevin C. Conlon, E. Lake Potter, Stefania Pittaluga, Chyi-Chia Richard Lee, Milos D. Miljkovic, Thomas A. Fleisher, Sigrid Dubois, Bonita R. Bryant, Michael Petrus, Liyanage P. Perera, Jennifer Hsu, William D. Figg, Cody J. Peer, Joanna H. Shih, Jason L. Yovandich, Stephen P. Creekmore, Mario Roederer, Thomas A. Waldmann
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4945–4954.
https://doi.org/10.1158/1078-0432.CCR-18-3468
Published: 15 August 2019
View article titled, IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Open the PDF for IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion in another window
Includes: Supplementary data
Journal Articles

Jumping the Barrier: Modeling Drug Penetration across the Blood–Brain Barrier

Cody J. Peer, Cindy H. Chau, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7437–7439.
https://doi.org/10.1158/1078-0432.CCR-17-2741
Published: 14 December 2017
View article titled, Jumping the Barrier: Modeling Drug Penetration across the Blood–Brain Barrier
Open the PDF for Jumping the Barrier: Modeling Drug Penetration across the Blood–Brain Barrier in another window
Journal Articles

Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma

Austin G. Duffy, Chi Ma, Susanna V. Ulahannan, Osama E. Rahma, Oxana Makarova-Rusher, Liang Cao, Yunkai Yu, David E. Kleiner, Jane Trepel, Min-Jung Lee, Yusuke Tomita, Seth M. Steinberg, Theo Heller, Baris Turkbey, Peter L. Choyke, Cody J. Peer, William D. Figg, Brad J. Wood, Tim F. Greten
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (16): 4633–4641.
https://doi.org/10.1158/1078-0432.CCR-16-3171
Published: 14 August 2017
View article titled, Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma
Open the PDF for Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Jung-Min Lee, Cody J. Peer, Minshu Yu, Lauren Amable, Nicolas Gordon, Christina M. Annunziata, Nicole Houston, Andrew K.L. Goey, Tristan M. Sissung, Bernard Parker, Lori Minasian, Victoria L. Chiou, Robert F. Murphy, Brigitte C. Widemann, William D. Figg, Elise C. Kohn
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (6): 1397–1406.
https://doi.org/10.1158/1078-0432.CCR-16-1546
Published: 14 March 2017
View article titled, Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Open the PDF for Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer in another window
Includes: Supplementary data
Journal Articles

Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells

Mahadev Rao, Scott M. Atay, Vivek Shukla, Young Hong, Trevor Upham, R. Taylor Ripley, Julie A. Hong, Mary Zhang, Emily Reardon, Patricia Fetsch, Markku Miettinen, Xinmin Li, Cody J. Peer, Tristan Sissung, William D. Figg, Assunta De Rienzo, Raphael Bueno, David S. Schrump
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1197–1210.
https://doi.org/10.1158/1078-0432.CCR-14-3379
Published: 29 February 2016
View article titled, Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
Open the PDF for Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells in another window
Includes: Supplementary data
Journal Articles

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Michael S. Gordon, Francisco Robert, Daniela Matei, David S. Mendelson, Jonathan W. Goldman, E. Gabriela Chiorean, Robert M. Strother, Ben K. Seon, William D. Figg, Cody J. Peer, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, Lee S. Rosen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (23): 5918–5926.
https://doi.org/10.1158/1078-0432.CCR-14-1143
Published: 30 November 2014
View article titled, An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer
Open the PDF for An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer in another window
Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

Beata Holkova, Maciej Kmieciak, E. Brent Perkins, Prithviraj Bose, Rachid C. Baz, G. David Roodman, Robert K. Stuart, Viswanathan Ramakrishnan, Wen Wan, Cody J. Peer, Jana Dawson, Loveleen Kang, Connie Honeycutt, Mary Beth Tombes, Ellen Shrader, Caryn Weir-Wiggins, Martha Wellons, Heidi Sankala, Kevin T. Hogan, A. Dimitrios Colevas, L. Austin Doyle, William D. Figg, Domenico Coppola, John D. Roberts, Daniel Sullivan, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5652–5662.
https://doi.org/10.1158/1078-0432.CCR-14-0805
Published: 13 November 2014
View article titled, Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms
Open the PDF for Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (21): 5392–5402.
https://doi.org/10.1158/1078-0432.CCR-14-0968
Published: 30 October 2014
View article titled, A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Open the PDF for A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers

Laleh Amiri-Kordestani, Victoria Luchenko, Cody J. Peer, Kambiz Ghafourian, James Reynolds, Deb Draper, Robin Frye, Sue Woo, David Venzon, John Wright, Monica Skarulis, William D. Figg, Tito Fojo, Susan E. Bates, Richard L. Piekarz
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4499–4507.
https://doi.org/10.1158/1078-0432.CCR-13-0095
Published: 13 August 2013
View article titled, Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers
Open the PDF for Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers in another window
Includes: Supplementary data
Journal Articles

Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia

Cody J. Peer, Tristan M. Sissung, AeRang Kim, Lokesh Jain, Sukyung Woo, Erin R. Gardner, C. Tyler Kirkland, Sarah M. Troutman, Bevin C. English, Emily D. Richardson, Joel Federspiel, David Venzon, William Dahut, Elise Kohn, Shivaani Kummar, Robert Yarchoan, Giuseppe Giaccone, Brigitte Widemann, William D. Figg
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2099–2107.
https://doi.org/10.1158/1078-0432.CCR-11-2484
Published: 01 April 2012
View article titled, Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Open the PDF for Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia in another window
Includes: Supplementary data